Alexion's Defensive Play Poised To Pay Off

Listen to this article

The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.

Alexion Pharmaceuticals Inc. scored an important win for its defensive strategy on its all-important Soliris (eculizumab) franchise. The firm's next-generation long-acting C5 complement inhibitor, ALXN1210, performed as well as Soliris in a Phase III clinical trial in treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) dosed every eight weeks, versus every two-week dosing for Soliris.

Management said it is on track to submit regulatory filings for ALXN1210 in the US, Europe and Japan in the...

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone

Feb 04 2026

• By Urtė Fultinavičiūtė

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod

Aug 15 2024

• By Alaric DeArment

US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.

Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III

Jul 24 2024

• By Jessica Merrill

The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.